ArticleACS omega2026
Fibroblast-Derived Decellularized Extracellular Matrix as a Bioactive Substrate for Osteoblast Activation.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extracellular matrix (ECM) plays a critical role in regulating cell behavior and is increasingly incorporated into biomaterial design. However, the reproducible generation of cell-derived ECM remains challenging due to variability in decellularization methods. This study refines a detergent-based protocol for preparing fibroblast-derived ECM and evaluates its effects on primary human osteoblasts (HOBs). Modifications to detergent exposure and processing conditions enhanced DNA removal (up to 98.3%) while preserving protein content, with residual DNA predominantly below 100 bp. Proteomic analysis was included as a descriptive, contextual reference and is not directly linked to functional results. Functional assays demonstrated that fibroblast-derived ECM modulated osteoblast responses in a concentration-dependent manner. A concentration of 1.25 mg/mL increased alkaline phosphatase activity and significantly increased RUNX2 levels, indicating enhanced early osteogenic signaling. Mineralization assessment at day 14 using Alizarin Red S and von Kossa staining revealed increased calcium and phosphate deposition in dECM-treated cultures compared with controls, suggesting progression toward matrix mineralization. Overall, the fibroblast-derived dECM provides a biologically active substrate that supports osteoblast function and osteogenic responses. Further studies are required to fully establish its osteogenic potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.